Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults

L. Watson, B. J. Wilson, Norman Robert Waugh

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

Pneumococcal polysaccharide vaccine is recommended in western countries for individuals at high risk of pneumococcal illness. We undertook a systematic review of randomised controlled trials of pneumococcal vaccine in adults, to determine the effects on clinical outcomes. Results: In industrialised populations, no benefit was detected for outcomes other than pneumococcal bacteraemia, and thin, did not reach statistical significance. In non-industrial populations, clear benefit was demonstrated for mortality and all-cause pneumonia. Conclusion: Benefit from pneumococcal vaccination depends on the baseline risk of infection and characteristics of a given population. Evidence from randomised trials for widespread adult vaccination in industrial countries is lacking. (C) 2002 Elsevier Science Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)2166-2173
Number of pages7
JournalVaccine
Volume20
Issue number17-18
DOIs
Publication statusPublished - 2002

Keywords

  • vaccination
  • pneumococcal
  • review
  • RANDOMIZED CONTROLLED TRIALS
  • OBSTRUCTIVE PULMONARY-DISEASE
  • PROTECTIVE EFFICACY
  • ELDERLY PEOPLE
  • PNEUMONIA
  • QUALITY
  • RECOMMENDATIONS
  • METAANALYSIS
  • PREVENTION
  • SEROTYPE

Cite this